Description
An AT1 receptor antagonist (IC50 = 2.7 nM); 20,000-fold selective for AT1 over AT2; does not alter PPARγ activity in vitro; increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes at 30 mg/kg ,
Formal name: N-(1-oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine
Synonyms: CGP 48933
Molecular weight: 435.5
CAS: 137862-53-4
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Heart Failure||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension